Clinical and Therapeutic Challenges in Aggressive Diffuse Large B-Cell Lymphoma of Immune-Privileged Sites: A Case Report of Orbital and Cervical Involvement in an End-Stage Renal Disease (ESRD) Patient

侵袭性弥漫性大B细胞淋巴瘤在免疫豁免部位的临床和治疗挑战:一例终末期肾病(ESRD)患者眼眶和颈部受累的病例报告

阅读:2

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. We report a rare and diagnostically complex case of aggressive DLBCL manifesting in immune-privileged and atypical extranodal sites of the head and neck, including bilateral retrobulbar regions, optic nerves, zygomatic muscle, cervical soft tissues, and paraspinal musculature, in a 70-year-old male patient with multiple comorbidities including end-stage renal disease (ESRD) and prior cerebrovascular accident. The patient presented with rapidly progressive bilateral proptosis and systemic signs of sepsis. Diagnostic imaging, constrained by renal insufficiency, revealed multifocal soft tissue masses without intracranial involvement. Histopathology and immunohistochemistry confirmed nongerminal center subtype DLBCL (CD20+, BCL2+, MUM1+, MYC-, CD3-, CD7-). Bone marrow analysis excluded systemic leukemic-phase disease. Due to the patient's frailty and organ dysfunction, standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy was contraindicated; a modified immunochemotherapy with corticosteroids and rituximab was initiated, yielding a partial reduction in tumor size. Despite initial improvement, the patient succumbed to complications of multiorgan failure. This case highlights the clinical and therapeutic challenges in diagnosing and managing extranodal DLBCL in elderly, immunocompromised patients, especially when the disease involves immune-privileged sites and standard diagnostic tools are limited.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。